Vascular mild cognitive impairment, VaMCI
Conditions
Interventions
experimental group:System Name: Neurofeedback Cognitive Rehabilitation Training System
Source: Shandong Haitian Intelligent Engineering Co., LTD
Specification and Model: HTR-NJRZ-I
control group:Name: Cognitive Rehabilitation Training and Assessment Software
Source: Produced by Hangzhou Jizhi Medical Technology Co., LTD. (Provided by Shandong Haitian Intelligent Engineering Co.,
Sponsors
The First Medical Center of the PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18 to 85 years old; (2) Subjects who meet the diagnostic criteria for Vascular Cognitive Impairment (VCI) and are classified as having mild VCI according to the severity of cognitive impairment; (3) Montreal Cognitive Assessment (MoCA) score of less than 26 points during the screening period; (4) Clinical Dementia Rating (CDR) scale score of 0.5; (5) Having sufficient visual and auditory discrimination ability to undergo neuropsychological tests; (6) Subjects shall have a stable and reliable caregiver, or be able to contact the caregiver frequently (at least 10 hours per week or more). The caregiver shall assist the patient in participating in the entire research process, and must have sufficient interaction and communication with the patient to provide valuable information for the scoring of the subject's various mental status scales; (7) Having a certain educational level, and being able to read simple newspaper articles and write simple essays in the past; (8) Those who voluntarily participate in the clinical study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with memory deficits that appear early and deteriorate progressively, prominent Parkinson's disease features in the early stage, or primary neurological diseases (such as multiple sclerosis, encephalitis, etc.); (2) Patients with diseases that can explain cognitive impairment (e.g., brain tumors, poisoning), as well as systemic diseases and metabolic abnormalities that significantly affect cognitive function; (3) Patients with other diseases that interfere with the evaluation of cognitive function, including alcoholism (regular drinking with an average alcohol intake of >60g/day for men and >40g/day for women; calculation of alcohol amount: Alcohol amount (g) = Alcohol consumption (ml) × Alcohol content %(V/V) × 0.8 (g/ml)), drug addiction, or abuse of other psychotropic drugs; (4) Patients with severe abnormalities in cardiac, hepatic, or renal function (New York Heart Association (NYHA) classification of cardiac function >= Grade 3, or alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), or creatinine (Cr) levels exceeding 2.5 times the upper limit of the normal range); (5) Patients with implanted metal medical electronic devices in the body, such as cardiac pacemakers; (6) Patients with limited limb movement who cannot normally participate in cognitive function training; (7) Pregnant or lactating women; (8) Patients who cannot cooperate with treatment; (9) Patients who have participated in other interventional clinical studies within 3 months before screening; (10) Patients deemed unsuitable for enrollment by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment Scale (MoCA); | — |
Secondary
| Measure | Time frame |
|---|---|
| Mini-Mental State Examination Score, MMSE; | — |
Countries
China
Contacts
Public ContactZhao Dong
The First Medical Center of the PLA General Hospital
Outcome results
None listed